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Default Treatment Strategy for
Drug-Eluting Stent Restenosis?*
Antonio Colombo, MD,yz Neil Ruparelia, MBBS, DPHILyzxSEE PAGES 14 AND 23I n 2001, when Morice et al. (1) presented theinitial results of RAVEL (The Randomized StudyWith the Sirolimus-Coated Bx Velocity Balloon-
Expandable Stent in the Treatment of Patients With
De Novo Native Coronary Artery Lesions), showing
0% angiographic restenosis 6 months after implanta-
tion of a sirolimus-eluting stent, very few people
would have envisaged that more than 10 years later,
there would be a need for a trial to evaluate the
best treatment strategy for drug-eluting stent (DES)
in-stent restenosis (ISR).
Although widespread use of DES (versus bare-
metal stents [BMS]), advances in stent design, and
greater operator experience have all signiﬁcantly
reduced the incidence of restenosis and resultant
target vessel revascularization (2), a low rate of ISR
continues to exist and it is not benign. Outcomes
are even poorer for those with DES compared with
individuals presenting with BMS-ISR (3).
There are several treatment options for DES-ISR
(e.g., repeat percutaneous coronary intervention,
plain old balloon angioplasty, cutting balloons, and
drug-eluting balloon [DEB] treatment). Current evi-
dence supports the use of a paclitaxel DEB, which has
been shown to be superior for the treatment of both
BMS-ISR and DES-ISR compared with the use of plain
old balloon angioplasty. An alternative approach for*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the yDepartment of Interventional Cardiology, San Raffaele
Scientiﬁc Institute, Milan, Italy; zDepartment of Interventional Car-
diology, EMO-GVM Centro Cuore Columbus, Milan, Italy; and the
xDepartment of Cardiology, Imperial College, London, United Kingdom.
Both authors have reported that they have no relationships relevant to
the contents of this paper to disclose.DES-ISR is another DES, with the ﬁrst-generation
paclitaxel DES demonstrating similar efﬁcacy to a
paclitaxel DEB (4,5). However, there is a paucity of
data examining the role of second-generation DES,
and long-term outcome data beyond 1 year are
completely lacking.In this issue of the Journal, 2 important studies
address the optimal treatment of DES-ISR. Alfonso
et al. (6) report the results of the prospective, multi-
center, open-label, randomized RIBS IV (Restenosis
Intra-Stent: Drug-Eluting Balloon vs. Everolimus-
Eluting Stent) study. The investigators evaluated
the role of second-generation everolimus-eluting
stents (EES) versus paclitaxel DEB for the treatment
of DES-ISR. Also, Habara et al. (7) report the ﬁndings
of a retrospective single-center investigation of con-
secutive patients presenting with ISR treated with
paclitaxel DEB addressing early and late angiographic
ﬁndings with clinical follow-up.
There are several important factors to consider
before interpreting the results of these studies.
Patients presenting with DES-ISR have already failed
the best currently available antirestenosis treatment;
thus, the challenge of achieving an acceptable long-
term result is more difﬁcult. Whereas mechanical
factors (e.g. stent underexpansion, stent fracture)
or technical factors (e.g. residual uncovered athero-
sclerotic plaque) may account for some instances
of DES-ISR, the most important potential mechanism
is tissue hyperplasia with resistance to antipro-
liferative drugs or hypersensitivity to the stent (8).
The large volume of hyperplastic tissue represents
a baseline problem for any technology relying
solely on balloon dilation. Treatment with DEB is
therefore unlikely to achieve acute luminal gain to
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35the same extent as another stent that can compress
this tissue.
Despite these limitations, the impetus to evaluate
the efﬁcacy of DEB treatment for DES-ISR is driven
by the concern of the negative long-term effects
on the coronary vessel associated with multiple
metal layers (9). Furthermore, DEB use may be more
favorable in certain patients who cannot continue
long-term dual antiplatelet therapy or those already
presenting with multiple stent layers as a conse-
quence of recurrent resistant DES-ISR.
In RIBS IV (6), 309 patients presenting with
DES-ISR were randomized to treatment with DEB
(n ¼ 154) or EES (n ¼ 155). There were no signiﬁcant
differences between groups in regard to baseline
clinical or procedural characteristics. Importantly,
lesions included were not of high complexity and
those at greatest risk of recurrence (lesions >30 mm,
in-stent total occlusion) were excluded. The in-
vestigators highlighted their careful attention to
lesion preparation to ensure no adjacent vessel
damage or geographical miss, with liberal use of
adjunctive intravascular imaging if indicated, all of
which contributed to a 100% angiographic success
rate. Both treatment strategies appeared to be tech-
nically feasible with a low crossover rate (5 patients in
the DEB group, 1 patient in the DES group). In this
context, DEB use was favorable with a late loss of
around 0.30 mm, similar to that reported in the
ISAR-DESIRE 3 (Intracoronary Stenting and Angio-
graphic Results: Drug Eluting Stents for In-Stent
Restenosis: 3) study (4). In comparison, treatment
with EES resulted in a late loss of 0.18 mm, which,
when considered in the setting of higher acute gain,
resulted in a larger vessel lumen at follow-up.
In-segment luminal diameter, the primary
endpoint evaluated in 90% of all eligible patients at
follow-up (median interval: 247 days), was signiﬁ-
cantly greater in the EES group (2.03  0.7 vs. 1.80 
0.6; p < 0.01) and appeared to be true across
numerous pre-speciﬁed variables (although the study
was not powered for subgroup analysis). Other
angiographic ﬁndings including net gain, loss index,
and late loss also appeared to favor EES treatment.
Differences in clinical events in the ﬁrst year favored
EES and were driven by target lesion revasculariza-
tion (TLR) (19 in the DEB group and 6 in the EES
group), with no differences in deﬁnite stent throm-
bosis, myocardial infarction, cardiac death, and
all-cause mortality.
The study by Habara et al. (7) reports long-term
results after treatment of consecutive patients pre-
senting to a single center with ISR and treated with
a paclitaxel DEB. Of the 468 patients (550 ISRlesions) treated, the majority (436 lesions) were for
DES-ISR with the remaining 114 lesions for BMS-ISR.
In addition to clinical follow-up, the patients un-
derwent early (6 to 12 months, 89% of lesions) and
late (12 to 24 months, 88% of lesions) angiographic
follow-up.
Pre-dilation was performed before DEB treatment
for all lesions, and balloon length was chosen to cover
the lesion by at least 2 mm at both the proximal and
distal margins. Keeping with current guidelines, the
recommended inﬂation time was 60 seconds. Binary
restenosis was deﬁned as stenosis occupying >50% of
the lumen of the vessel and late restenosis was
deﬁned as diameter stenosis $50% in lesions that
had <50% diameter stenosis at early follow-up.
At early angiographic follow-up, recurrent reste-
nosis occurred in 13 lesions (13%) in the BMS-ISR
group and in 82 lesions (21.1%) in the DES-ISR
group. This resulted in TLR being performed in 7
lesions (7%) in the BMS group and 54 lesions (13.9%)
in the DES-ISR group (p ¼ 0.002), which supports
previous studies suggesting better efﬁcacy of DEB
treatment in BMS-ISR lesions (10,11) compared with
efﬁcacy of DES-ISR treatment (12).
The most notable ﬁnding, however, was a “second
wave” of late loss in DES-ISR lesions when assessed
by late angiographic follow-up. Late restenosis was
signiﬁcantly greater in the DES-ISR group (50 lesions,
16.8%) compared with 2 lesions (2.5%) in the BMS-ISR
group (p < 0.001). Delayed late loss was also signiﬁ-
cantly greater in the DES-ISR group (0.09  0.29 mm
vs. 0.22  0.50 mm; p ¼ 0.004) and did not appear
to be related to the type of DES initially implanted,
with 70% of original lesions treated with a ﬁrst-
generation DES and 30% with a second-generation
DES (binary restenosis: 21.8% vs. 19.5%; p ¼ 0.61;
TLR: 14.9% vs. 11.5%; p ¼ 0.38; late lumen loss: 0.32 
0.23 mm vs. 0.23  0.53 mm; p ¼ 0.12). These angio-
graphic ﬁndings translated to a signiﬁcant difference
in TLR at 24 months (8.7% BMS-ISR vs. 24.2%
DES-ISR; log rank p ¼ 0.003). There were no dif-
ferences between groups with regard to the com-
posite endpoints of cardiac death, myocardial
infarction, or target lesion thrombosis at 24 months
(log rank p ¼ 0.8).
Have the results of these 2 important studies
marginalized the role of DEB for the treatment of
DES-ISR? We still lack a deﬁnitive answer. Advocates
of DEB treatment may state that better lesion prepa-
ration with a cutting or scoring balloon may have
resulted in better acute gain. Furthermore, all
currently available DEB are coated with paclitaxel due
to its lipophilic properties. However, paclitaxel has
now been superseded by sirolimus (and its analogues)
Colombo and Ruparelia J A C C V O L . 6 6 , N O . 1 , 2 0 1 5
DES as the Default Strategy for DES Restenosis J U L Y 7 , 2 0 1 5 : 3 4 – 6
36in the setting of DES as the antiproliferative drug of
choice due to its superiority (13). By virtue of its
pharmacology, the ability to deliver adequate siro-
limus drug doses to the vessel wall with current
balloon delivery systems has hampered its use. Novel
drug delivery technologies in development may
enable production of sirolimus-eluting balloons (14).
Therefore, the proven superior antiproliferative ac-
tion of limus compounds versus paclitaxel demon-
strated with metal stents (13) also may be true with
DEB treatment. Finally, longer-term angiographic
and clinical follow-up data are required before
deﬁnitively concluding that EES is superior to DEB
for DES-ISR.
Another approach that should be considered for
the treatment of DES-ISR is the use of bioresorbable
scaffolds, which theoretically would achieve excel-
lent acute gain without the potential long-term
consequences of an additional metal layer in the
vessel wall. However, the advantages (e.g., positiveremodeling) associated with scaffold use would be
nulliﬁed by the presence of the previous metal stent.
Currently, we can conclude that the use of EES
for DES-ISR is safe and effective but the role of
DEB in this context is limited. However, unan-
swered questions remain. Is it possible to identify
some DES-ISR lesions where DEB treatment would
be equivalent or superior to EES? Will a new limus
DEB be better than current paclitaxel DEB for the
treatment of DES-ISR and therefore challenge the
results of RIBS IV? While awaiting new data,
the strategy of stenting a stent, even if not per-
ceived as particularly elegant, should be the
default approach for most lesions presenting with
DES restenosis.
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